Thus, HPS can potentially prevent early DN and slow down neuropathy in diabetes by inhibiting the expression of CTGF, TGF-β1, PKC, TIMP-1, and VEGF proteins, increasing MMP-2 levels, and reducing serum creatinine, urea nitrogen, and 24-hour urine microalbumin levels. This evidence concerns the gene VEGFA and liver dysplastic nodule.